Regenxbio (RGNX) Cash & Current Investments (2014 - 2026)

Regenxbio's Cash & Current Investments history runs 12 years deep, the most recent figure standing at $230.1 million for Q4 2025.

• In Q4 2025, Cash & Current Investments fell 1.97% year-over-year to $230.1 million; the TTM figure through Dec 2025 stood at $230.1 million (down 1.97% YoY), while the FY2025 annual figure was $230.1 million, down 1.97% from the prior year.
• Cash & Current Investments for Q4 2025 stood at $230.1 million, down from $274.2 million in the prior quarter.
• The five-year high for Cash & Current Investments was $457.4 million in Q4 2021, with the low at $230.1 million in Q4 2025.
• The 5-year median for Cash & Current Investments is $327.6 million (2023), against an average of $330.0 million.
• The sharpest annual moves came in 2021 and 2023: Cash & Current Investments soared 57.88% in 2021, then fell 24.51% in 2023.
• Regenxbio's Cash & Current Investments stood at $457.4 million in 2021, then declined by 20.29% to $364.6 million in 2022, then dropped by 24.51% to $275.3 million in 2023, then decreased by 14.74% to $234.7 million in 2024, then retreated by 1.97% to $230.1 million in 2025.
• Business Quant data shows RGNX's Cash & Current Investments at $230.1 million in Q4 2025, $274.2 million in Q3 2025, and $323.3 million in Q2 2025.